Evidence map›Paper›PMID 36093336›Full record

ArticlePeerJ2022

Benchmark datasets for SARS-CoV-2 surveillance bioinformatics.

Lingzi Xiaoli, Jill V Hagey, Daniel J Park, Christopher A Gulvik, Erin L Young, Nabil-Fareed Alikhan, Adrian Lawsin, Norman Hassell, Kristen Knipe, Kelly F Oakeson and 16 more

Abstract read
In one paragraph

Article in PeerJ, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Lingzi Xiaoli *Strain Surveillance and Emerging Variant Team, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Jill V Hagey *Strain Surveillance and Emerging Variant Team, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Daniel J ParkBroad Institute of MIT and Harvard, Cambridge, MA, United States of America.
Christopher A GulvikStrain Surveillance and Emerging Variant Team, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Erin L YoungUtah Public Health Laboratory, Salt Lake City, UT, United States of America.
Nabil-Fareed AlikhanQuadram Institute Bioscience, Norwich Research Park, Norwich, United Kingdom.
Adrian LawsinStrain Surveillance and Emerging Variant Team, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Norman HassellStrain Surveillance and Emerging Variant Team, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Kristen KnipeStrain Surveillance and Emerging Variant Team, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Kelly F OakesonUtah Public Health Laboratory, Salt Lake City, UT, United States of America.
Adam C RetchlessStrain Surveillance and Emerging Variant Team, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Migun ShakyaBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, United States of America.
Chien-Chi LoBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, United States of America.
Patrick ChainBioscience Division, Los Alamos National Laboratory, Los Alamos, NM, United States of America.
Andrew J PageQuadram Institute Bioscience, Norwich Research Park, Norwich, United Kingdom.
Benjamin J MetcalfStrain Surveillance and Emerging Variant Team, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Michelle SuStrain Surveillance and Emerging Variant Team, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Jessica RowellSARS-CoV-2 Emerging Variant Sequencing Project Dry Lab Group Laboratory and Testing Task Force COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Eshaw VidyaprakashSARS-CoV-2 Emerging Variant Sequencing Project Dry Lab Group Laboratory and Testing Task Force COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Clinton R PadenStrain Surveillance and Emerging Variant Team, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Andrew D HuangSARS-CoV-2 Emerging Variant Sequencing Project Dry Lab Group Laboratory and Testing Task Force COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Dawn RoelligStrain Surveillance and Emerging Variant Team, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Ketan PatelStrain Surveillance and Emerging Variant Team, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Kathryn WingleeStrain Surveillance and Emerging Variant Team, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Michael R WeigandStrain Surveillance and Emerging Variant Team, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Lee S KatzStrain Surveillance and Emerging Variant Team, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.

Funding

Viral Genomics: evolution, spread, and host interactionsU19AI110818 · NIAID · BROAD INSTITUTE, INC. · PI SABETI, PARDIS CHRISTINE · 2014 to 2024
$66.5M
Biotechnology and Biological Sciences Research Council BB/CCG1860/1Biotechnology and Biological Sciences Research Council BB/R012504/1Biotechnology and Biological Sciences Research Council BBS/E/F/000PR10352NIAID NIH HHS U19 AI110818
6 · The paper itself

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread globally and is being surveilled with an international genome sequencing effort. Surveillance consists of sample acquisition, library preparation, and whole genome sequencing. This has necessitated a classification scheme detailing Variants of Concern (VOC) and Variants of Interest (VOI), and the rapid expansion of bioinformatics tools for sequence analysis. These bioinformatic tools are means for major actionable results: maintaining quality assurance and checks, defining population structure, performing genomic epidemiology, and inferring lineage to allow reliable and actionable identification and classification. Additionally, the pandemic has required public health laboratories to reach high throughput proficiency in sequencing library preparation and downstream data analysis rapidly. However, both processes can be limited by a lack of a standardized sequence dataset. Methods: We identified six SARS-CoV-2 sequence datasets from recent publications, public databases and internal resources. In addition, we created a method to mine public databases to identify representative genomes for these datasets. Using this novel method, we identified several genomes as either VOI/VOC representatives or non-VOI/VOC representatives. To describe each dataset, we utilized a previously published datasets format, which describes accession information and whole dataset information. Additionally, a script from the same publication has been enhanced to download and verify all data from this study. Results: The benchmark datasets focus on the two most widely used sequencing platforms: long read sequencing data from the Oxford Nanopore Technologies platform and short read sequencing data from the Illumina platform. There are six datasets: three were derived from recent publications; two were derived from data mining public databases to answer common questions not covered by published datasets; one unique dataset representing common sequence failures was obtained by rigorously scrutinizing data that did not pass quality checks. The dataset summary table, data mining script and quality control (QC) values for all sequence data are publicly available on GitHub: https://github.com/CDCgov/datasets-sars-cov-2. Discussion: The datasets presented here were generated to help public health laboratories build sequencing and bioinformatics capacity, benchmark different workflows and pipelines, and calibrate QC thresholds to ensure sequencing quality. Together, improvements in these areas support accurate and timely outbreak investigation and surveillance, providing actionable data for pandemic management. Furthermore, these publicly available and standardized benchmark data will facilitate the development and adjudication of new pipelines.

Indexed as

COVID-19SARS-CoV-2BenchmarkingComputational BiologyHumansSequence AnalysisBenchmarkingCOVID-19sha256StandardizationWGS

Identifiers

PMID36093336
PMCPMC9454940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.